Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Journal Articles and Abstracts

5-25-2018

Substance-induced anxiety disorder after one dose
of 3,4-methylenedioxymethamphetamine: a case
report.
Kaeley Kaplan
Swedish First Hill Family Medicine Residency, Swedish Medical Center, 1401 Madison Street, Suite 100, Seattle, WA, 98104,
USA

Fiona Kurtz
Swedish First Hill Family Medicine Residency, Swedish Medical Center, 1401 Madison Street, Suite 100, Seattle, WA, 98104,
USA

Kelly Serafini
Swedish First Hill Family Medicine Residency, Swedish Medical Center, 1401 Madison Street, Suite 100, Seattle, WA, 98104,
USA

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Behavioral Medicine Commons, and the Primary Care Commons
Recommended Citation
Kaplan, Kaeley; Kurtz, Fiona; and Serafini, Kelly, "Substance-induced anxiety disorder after one dose of
3,4-methylenedioxymethamphetamine: a case report." (2018). Journal Articles and Abstracts. 365.
https://digitalcommons.psjhealth.org/publications/365

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Journal
Articles and Abstracts by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.

Kaplan et al. Journal of Medical Case Reports (2018):4
https://doi.org/10.1186/s13256-018-1670-7

CASE REPORT

Open Access

Substance-induced anxiety disorder after one
dose of 3,4-methylenedioxymethamphetamine:
a case report
Kaeley Kaplan1*, Fiona Kurtz1,2 and Kelly Serafini1

Abstract
Background: In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after
a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary
Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and
treating this rare mental health disorder.
Case presentation: Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a
35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic
symptoms. He was initially treated with a combination of behavioral therapy and the serotonin agonist
buspirone. Buspirone ultimately proved ineffective, so it was discontinued in favor of the selective serotonin
reuptake inhibitor sertraline. While awaiting the pharmacological onset of sertraline, the patient worked with
a behavioral health consultant, who provided psychoeducation on the experience of panic, building
relaxation skills, and modifying maladaptive thought patterns. Enhanced communication between the primary
care provider and behavioral health consultant facilitated the planning and enactment of the patient’s care
plan. Approximately 2.5 months after his initial ingestion of 3,4-methylenedioxymethamphetamine, the
patient’s symptoms subsided. This improvement was attributed to the combination of the behavioral health
intervention and sertraline at a dose of 50 mg daily. Six months after 3,4-methylenedioxymethamphetamine
ingestion, the patient began to gradually taper sertraline and has had no resurgence of anxiety symptoms
to date.
Conclusions: Our patient’s case not only demonstrates a rare presentation of 3,4-methylenedioxymethamphetamineinduced anxiety disorder but also provides support for the use of the Primary Care Behavioral Health model to deliver
individualized, timely mental health care in a primary care setting.
Keywords: Substance-induced anxiety disorder, 3,4-Methylenedioxymethamphetamine, MDMA, Selective
serotonin reuptake inhibitor, Mental health, Primary care
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Background
3,4-Methylenedioxymethamphetamine (MDMA), more
commonly known as “molly” in its pure form and as “ecstasy” historically, is a drug that gained popularity in the
1980s and continues to be used around the world [1, 2].
Current data suggest that MDMA use is prevalent in the
United States. According to the 2014 National Survey
on Drug Use and Health, approximately 609,000 people
over the age of 12 years had used MDMA in the previous
month, and among adults aged 26 years or older, 6.5%
reported lifetime use of MDMA, and 0.1% reported
MDMA use in the previous month [2]. Recreational
users have reported that the drug induces “feelings of
intimacy and closeness to others” and “positive mood”
[3, 4]. Acute (< 1 day) and subacute (1–7 days) negative
effects of the drug include confusion/delirium, loss of
appetite, insomnia, panic/anxiety, low mood/depression,
and difficulty concentrating, with low mood typically occurring 3–4 days after MDMA use [4]. The longer-term
psychological effects of MDMA are more difficult to define, in part because many MDMA users are polydrug
users and in part because of the high prevalence of comorbid disorders such as depression, anxiety, and insomnia
[1]. Even less is known about the possible long-term effects of a one-time dose of MDMA, though several case
reports, including the present one, highlight lasting effects
after a single dose [5, 6].
The drug’s chief psychopharmacological target is the
monoaminergic system, which plays a role in emotional
regulation and physiological arousal [1, 7]. Research in
rodents and nonhuman primates has consistently demonstrated an MDMA-triggered release of dopamine, norepinephrine, and serotonin from nerve terminals [7, 8].
Repeated doses of MDMA lead to damage of serotonergic
nerve terminals, perhaps via increasing free radical activity, and there is concern and some clinical evidence for
long-term depletion of serotonin and changes to the serotonergic neural network in heavy users of MDMA [1, 7].
Alterations in serotonergic activity have long been
implicated in anxiety disorders, and feelings of panic/
hyperarousal are induced by increased activity of epinephrine and norepinephrine, adding strength to the hypothesis that MDMA use can elicit anxiety and panic
symptoms [9].
Patients’ concerns regarding illicit substance use (e.g.,
MDMA use) and mental health are increasingly addressed
and treated in the primary care setting. Primary care facilities provide an easily accessible and comfortable space to
discuss a wide range of medical and psychiatric concerns
[10]. In fact, 50–70% of people experiencing psychological
or behavioral conditions receive their treatment in primary care settings from primary care providers (PCPs)
[11, 12], and 80% of individuals with a mental health disorder report that they will visit their PCP at least one time
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within a calendar year [13]. Thus, PCPs are the most likely
health care providers to assess and treat substance use
concerns.
Recently, some pioneering medical clinics have begun
to adopt a Primary Care Behavioral Health (PCBH)
model with the aim of strengthening integration between
physical and mental health care. This approach is particularly applicable to and beneficial in treating patients
with depression, anxiety, posttraumatic stress disorder,
and substance use disorder symptoms or concerns. These
patients often benefit from both psychopharmacological
and behavioral health treatment. The PCBH model has a
population-based health focus and aims to meet the behavioral health needs of all patients receiving medical
treatment in primary care, including those who are more
likely to experience barriers to specialty mental health care
because of cost, language differences, stigma, and transportation difficulties [14]. Arguably one of the greatest
benefits of this integrated model is strengthened communication between mental health providers (commonly referred to as behavioral health consultants) and medical
care providers [14]. This enhanced communication facilitates unification of psychopharmacological and behavioral
health interventions and maximizes opportunities for PCPs
to receive treatment feedback, particularly with unique
cases. Given the novelty and complexity of substanceinduced psychiatric disorders, patients may benefit greatly
from the high level of communication and coordination
afforded by the PCBH model.
In this case report, we describe a patient who took a
single dose of MDMA that triggered substance-induced
anxiety disorder which lasted for several months. The
patient’s symptoms gradually improved and remitted
with a combination of medical and behavioral therapy in
a primary care office that had adopted principles of the
PCBH model. The PCP and behavioral health consultant
worked closely together and with the patient in providing comprehensive mental health care. This case
report highlights both an uncommon presentation of
substance-induced anxiety disorder and a unique approach to integrative mental health treatment.

Case presentation
A previously healthy 35-year-old Hispanic man with a
remote history of mild performance anxiety in late adolescence presented to our family medicine residency
clinic to establish and seek care for acute onset of anxiety. The patient was a manager at a large manufacturing
firm and had received a master’s degree. At the time of
presentation, he was married with two children. He had
no family history of mental illness and was not taking
prescription medications. At his initial visit at the clinic,
he reported that 9 days prior, he had taken one dose of
“molly” while at a gathering with friends. The friend
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who had supplied the drug stated that it was “pure
crystal MDMA.” According to the patient, this was his
first lifetime use of MDMA. He had also consumed several alcoholic drinks that night, reportedly reaching the
level of intoxication. He described having a “fine” experience with the drug and returned to his normal
baseline for the next 2 days. On the third day after
ingesting MDMA, he began to experience an increase
in worry and agitation; he reported having panicked
thoughts and development of palpitations, blurry vision,
flushing, increased thirst, and insomnia. He stated that
these symptoms increased over the coming days, prompting him to seek medical care. Regarding substance use history, the patient reported occasional social alcohol use
since his early 20s, rarely to excess. He had used cannabis
several times while in college (ages 18–22) and found that
this precipitated anxiety and therefore he did not continue
using it regularly. He denied any regular use of other illicit
substances.
On the initial day that the patient met with a medical
provider in the clinic, he reported a score of 20 (maximum score of 21) on the Generalized Anxiety Disorder
7-item scale [15], an anxiety screening and rating tool
commonly used in primary care offices. This score was
consistent with a severe level of anxiety. The patient was
prescribed buspirone, a serotonin 1A receptor (5-HT1A)
receptor agonist, with a plan to uptitrate to 15 mg twice
daily over the coming weeks. The patient was also referred
to the clinic’s behavioral health service for adjunctive
treatment and was promptly seen by a behavioral health
consultant for their first session the following day. This
initial visit involved an assessment of his biopsychosocial
history and mood, a functional analysis of his anxiety
symptoms, and a collaborative discussion regarding his
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treatment goals. Using interventions informed by cognitive behavioral therapy, the patient and the behavioral
health consultant aimed to increase his coping skills and
management of his anxiety symptoms and to improve his
overall quality of life (e.g., reduce distress, increase enjoyment at home, and increase productivity at work).
The patient was seen for follow-up every 7–10 days by
his PCP for the next month (see Table 1). Simultaneously, he received behavioral health treatment each
week following his first month of medical treatment in
the family medicine clinic. He then established a therapeutic relationship with a counselor outside the clinic,
where they reportedly engaged in talk therapy weekly.
The patient reported only a slight improvement in his
anxiety and panic symptoms despite the therapeutic
dose buspirone; therefore, he was prescribed a selective
serotonin reuptake inhibitor (SSRI) and a benzodiazepine and was referred to the psychiatry department for
additional consultation. The consulting psychiatrist was
concerned for MDMA-induced anxiety disorder and recommended discontinuation of buspirone and initiation
of low-dose sertraline with slow uptitration. The patient
benefited from behavioral health treatment specifically
aimed at enhancing understanding and controlling the
sympathetic nervous system (i.e., cognitive behavioral
modeling, psychoeducation on the cycle of panic, and
relaxation skill training). Behavioral health treatment
was especially important as he awaited the clinical effect
of his psychoactive medications.
Ongoing evaluation by the PCP, a consulting psychiatrist, and the behavioral health consultant supported a
diagnosis of substance-induced anxiety disorder. He experienced persistent anxiety (reporting daily worry, panic,
racing heart, dizziness, restlessness, and catastrophic

Table 1 Patient presentation and treatment timeline
Day 0

Patient reports having ingested MDMA

Day 3

Development of acute anxiety and physiological arousal

Day 9

Patient presents to clinic for evaluation and is prescribed uptitration of buspirone

Week 2

Patient is prescribed lorazepam

Week 3

Patient is taking full dose of buspirone with no significant improvement in anxiety; rare lorazepam use
Prescribed SSRI but does not start taking
First visit with behavioral health consultant, total of six visits every 1–4 weeks

Week 4

Seen by psychiatrist and given tentative diagnosis of substance-induced anxiety disorder
SSRI recommended

Week 6

Begins SSRI sertraline and begins buspirone taper

Week 7

Reports some improvement in anxiety and sleep

Week 7.5

Reports acute worsening of anxiety with suicidal ideation
Sertraline dose is lowered, and in 3 days, patient no longer has suicidal ideation

Weeks 8–10

Continues sertraline, reaching dose of 50 mg once daily with continued improvement in anxiety

Weeks 10+

Seen by psychiatrist 2, who concurs with diagnosis of substance-induced anxiety disorder
Patient continues sertraline 50 mg/day for several more months without resurgence of anxiety symptoms

MDMA 3,4-Methylenedioxymethamphetamine, SSRI Selective serotonin reuptake inhibitor
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thinking), and all of his symptoms developed shortly
after ingesting a single dose of MDMA. His symptoms
caused him significant distress and impairment in his
employment as well as his family life. The patient denied clinically significant anxiety directly prior to taking
MDMA; his only history of anxiety was performance
anxiety many years prior. Therefore, he did not meet
criteria for panic disorder or generalized anxiety disorder, because his symptom onset followed substance
ingestion. Simultaneously, the patient reported transdiagnostic depressive symptoms, including hopelessness, fatigue, maladaptive thinking, and low mood.
These symptoms, which also began following the patient’s use of MDMA, were etiologically attributed to
his anxious physiological symptoms and thoughts, in
particular the catastrophic and generalized worries that
this one-time drug use had “ruined” his life. Consequently, his symptoms appeared to be explained by the
substance-induced anxiety, as opposed to representing
a discrete depressive disorder.
The patient initially tolerated the sertraline well and
experienced a relatively rapid improvement in anxiety
symptoms while taking 25 mg daily. After 8 days of the
25-mg dose, the dose was increased to 37.5 mg. After 2
days at this dose, the patient developed abrupt onset of
suicidal ideation with a resurgence of anxiety and panic
symptoms. Given the gravity of these new symptoms,
the PCP and behavioral health consultant worked together and with the patient to devise a plan for ongoing
care. He was able to see the behavioral health consultant
for an urgent visit. The dose of sertraline was reduced to
25 mg, and plans were made for intensive outpatient
mental health treatment at a nearby hospital.
While awaiting entrance into that program, his suicidal
ideation and anxiety abated. As his symptoms improved,
the behavioral health consultant supplemented sympathetic nervous system training with thought identification
and cognitive retraining. These interventions served to address his reported catastrophic and demoralizing appraisals following the use of MDMA (e.g., “I am a terrible
person for taking that Molly,” and “I have ruined my life
forever”). He saw a second psychiatrist for additional recommendations. They concurred with the diagnosis of
substance-induced anxiety disorder and the prescribed
SSRI treatment. Eventually, the dose of sertraline was
slowly increased to 50 mg with continued improvement
in all symptoms and no further resurgence of suicidal
ideation. The patient’s anxiety and panic were not well
controlled until approximately 2.5 months after ingesting MDMA. At 6 months following his presentation, he
was doing well with a plan to slowly taper the sertraline. He expressed gratitude for an interdisciplinary
team approach and the unique benefits of skills training
in tandem with psychopharmacological treatment.
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Discussion
In our patient, a single dose of MDMA triggered anxiety
that lasted nearly 2.5 months and eventually improved
with the implementation of both psychopharmacological
and behavioral health techniques. We know of only one
other case report in which one dose of MDMA was reported to precipitate protracted anxiety and/or panic
symptoms [5], though given the general underreporting
of illicit substance use, the true number may be higher.
Clinicians should consider recent MDMA use as a potential etiology of acute anxiety.
Substance-induced mental health disorders are challenging not only to diagnose but also to treat, particularly
given the complex nature of substance interactions and
overall patient presentation. In our patient, the diagnosis
of substance-induced anxiety disorder was corroborated
by three separate practitioners (a behavioral health consultant and two independent psychiatrists). The patient
had denied any significant precipitants that may have triggered his anxiety, and there was a consistent temporal relationship between MDMA ingestion and his symptoms.
Although the treating providers had no reason to doubt
the patient’s stated history of one-time MDMA use, it is
possible that he unknowingly had ingested other or additional substances. The treating providers did not employ
a urine drug screen during the course of the patient’s
evaluation and treatment, chiefly because few substances
can be reliably detected 9 days postingestion. Therefore,
the patient’s MDMA use must be taken at face value as
the cause of his symptoms.
Medically speaking, initial treatment with the 5-HT1A
receptor agonist buspirone was not effective in relieving
the patient’s anxiety and should have been reserved as
an adjunctive treatment to an SSRI-based treatment
regimen, not as sole therapy. Offering a benzodiazepine
at the first visit may have helped the patient more quickly
gain control of his anxiety (it was not prescribed until the
second visit), though benzodiazepines can interfere with
cognitive behavioral therapy and should be deployed with
caution owing to concerns surrounding dependence and
abuse. It was not until uptitration of the SSRI sertraline
that the patient began to experience consistent symptomatic improvement. Notably, this patient did experience a
brief worsening of his anxiety while initiating sertraline;
this is a relatively common and well-known side effect of
SSRIs. In this case, the patient’s acute worsening of symptoms lasted only a few days. Many psychotropic therapies
take weeks to months to take effect, and a key component
of the patient’s care was timely access to mental health
care that served to alleviate symptoms while awaiting the
therapeutic effect of medications.
The PCBH model served to offer collaborative, interdisciplinary care that treated both his short-term and
long-term needs. The patient’s acute needs were met by
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psychopharmacological treatment aimed at reducing
his debilitating physiological panic and anxiety symptoms. The providers were able to offer long-term benefits by tailoring a behavioral health treatment plan that
helped the patient modify newly exacerbated maladaptive thought patterns (cognitive retraining) as well as
develop long-term behavioral skills to manage his
physiological symptoms (relaxation training).
His overall treatment was bolstered by adherence to
the PCBH model’s recommendation of frequent, efficient,
and consistent communication between multidisciplinary
team members [14]. Use of this approach prevented delays
in the patient’s treatment and enhanced treatment plan
development and agreement among team members. The
PCBH model has been found to be effective for treating
patients across the entire spectrum of mental health conditions [10]. The present case report corroborates such
findings and demonstrates the feasibility and benefits of
integrating behavioral and primary medical care [14]. The
PCBH model offers the advantage of combining the resources and knowledge of multiple providers in a single,
unified, and accessible setting.

Conclusions
This report describes a rare presentation of substanceinduced anxiety disorder after ingestion of a single dose
of MDMA. The patient’s symptoms were severe and
were addressed with a combination of behavioral health
and psychopharmacological therapies. His symptoms
stabilized and improved only after several months of behavioral health counseling and medical treatment with
the SSRI sertraline. We posit that his care was augmented
by the direct integration of his medical treatment with
his behavioral health treatment according to the PCBH
model. This integration allowed for timely communication between the patient’s behavioral health provider
and PCP and facilitated the assessment and treatment
of his unique mental health disorder.
Availability of data and materials
Data sharing is not applicable to this article, because no datasets were
generated or analyzed during the present study.

Authors’ contributions
KK and FK contributed the patient’s care as well as to research, writing, and
editing of the report. KS contributed to research and editing of the manuscript
and advising throughout patient care. All authors read and approved the final
manuscript.

Ethics approval and consent to participate
Informed consent for participation was obtained from the patient during his
treatment. Ethics review was not sought, because this study met criteria for a
case report, which is not considered human subject research according to
the Washington State Institutional Review Board and is therefore exempt
from requiring ethics committee approval.

Page 5 of 5

Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
Swedish First Hill Family Medicine Residency, Swedish Medical Center, 1401
Madison Street, Suite 100, Seattle, WA 98104, USA. 2Department of Clinical
Psychology, Seattle Pacific University, Seattle, WA, USA.
Received: 24 September 2017 Accepted: 28 March 2018

References
1. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological
effects. Psychopharmacology. 2000;152:230–48.
2. United States Department of Health and Human Services. Substance Abuse
and Mental Health Services Administration, Center for Behavioral Health
Statistics and Quality. National survey on drug use and health, 2014. Ann
Arbor: Inter-university Consortium for Political and Social Research; 2016.
https://doi.org/10.3886/ICPSR36361.v1. Accessed 9 July 2017.
3. Solowji N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of
‘ecstasy’ users and their experience with the drug. Br J Addict. 1992;87:1161–72.
4. Verheyden SL, Henry JA, Curran HV. Acute, sub-acute and long-term
subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular
users. Human Psychopharmacol. 2003;18:507–17.
5. McCann UD, Ricuarte GA. MDMA (“Ecstasy”) and panic disorder: induction
by a single dose. Biol Psychiatry. 1992;32:950–3.
6. Viava G, Boss V, Bailly D, Thomas P, Lestavel P, Goudemand M. An “accidental”
acute psychosis with ecstasy use. J Psychoactive Drugs. 2001;33:95–8.
7. Green AR, Mechan AO, Elliot JM, O’Shea E, Colado MI. The pharmacology
and clinical pharmacology of 3,4-methylenedioxymethamphetamine
(MDMA, “ecstasy”). Pharmacol Rev. 2003;55:463–508.
8. Ricaurte GA, DeLanney LE, Irwin I, Langston JW. Toxic effects of MDMA on
central serotonergic neurons in the primate: importance of route and
frequency of drug administration. Brain Res. 1998;446:165–8.
9. Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A. Modulation
of anxiety circuits by serotonergic systems. Stress. 2005;8:233–46.
10. Bryan CJ, Morrow C, Appolonio KK. Impact of behavioral health consultant
interventions on patient symptoms and functioning in an integrated family
medicine clinic. J Clin Psychol. 2009;65:281–93.
11. Gatchel RJ, Oordt MS. Clinical health psychology and primary care: practical
advice and clinical guidance for successful collaboration. Washington, DC:
American Psychological Association; 2003.
12. Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P,
Wells KB, Zaslavsky AM. Prevalence and treatment of mental disorders, 1990
to 2003. N Engl J Med. 2005;352:2515–23.
13. Narrow WE, Regier DA, Rae DS, Manderscheid RW, Locke BZ. Use of services
by persons with mental and addictive disorders: findings from the National
Institute of Mental Health Epidemiologic Catchment Area Program. Arch
Gen Psychiatry. 1993;50:95–107.
14. Hunter CL, Goodie JL. Operational and clinical components for integratedcollaborative behavioral healthcare in the patient-centered medical home.
Fam Syst Health. 2010;28:308–21.
15. Spitzer RL, Kroenke K, Williams JB, Löwe JB. A brief measure for assessing
generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7.

